Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary McManus

Nurse Practitioner, Psychiatric/Mental Health North Myrtle Beach, SC Nurse Practitioner

NPI 1316488836 CMS profile 10509668

2111 Highway 17 S Ste 3, North Myrtle Beach, SC 29582

Open in the dashboard

General payments

$14,987

587 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary McManus of North Myrtle Beach, SC is reported in the CMS Open Payments database as having received $14,987 across 587 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,503 110
2024 General $2,744 106
2023 General $2,733 113
2022 General $3,509 132
2021 General $2,498 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary McManus
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Mary McManus were reported at $3,503. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Mary McManus Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,498 $166 $54–$482 $132
2022 $3,509 $195 $66–$559 $149
2023 $2,733 $233 $82–$673 $160
2024 $2,744 $236 $84–$688 $164
2025 $3,503 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,171 154 payments
  2. Otsuka America Pharmaceutical, Inc. $1,445 49 payments
  3. ITI, Inc. $1,428 53 payments
  4. Teva Pharmaceuticals USA, Inc. $1,334 62 payments
  5. Neurocrine Biosciences, Inc. $1,222 40 payments
  6. Vanda Pharmaceuticals Inc. $888 32 payments
  7. Janssen Pharmaceuticals, Inc $726 19 payments
  8. Supernus Pharmaceuticals, Inc. $700 14 payments
  9. Axsome Therapeutics, Inc. $599 16 payments
  10. Alkermes, Inc. $595 22 payments
  11. Other $3,879 126 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,876 583 payments
  2. Education $111 4 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,679 121 payments
  2. REXULTI $1,289 46 payments
  3. AUSTEDO $1,182 59 payments
  4. INGREZZA $1,148 36 payments
  5. CAPLYTA $945 34 payments
  6. FANAPT $888 32 payments
  7. SPRAVATO $694 18 payments
  8. Auvelity $599 16 payments
  9. HETLIOZ $548 29 payments
  10. LYBALVI $535 19 payments
  11. Other $8,142 286 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,726

Median for Nurse Practitioner: 389

Drug cost

$133,577

Median for Nurse Practitioner: $21,885

Branded share of claims

24.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 28 $68,846
Adderall Xr Dextroamphetamine/Amphetamine Brand 11 $11,439
Vyvanse Lisdexamfetamine Dimesylate Brand 19 $7,063
Lurasidone Hcl Generic 16 $5,370
Bupropion Xl Bupropion Hcl Brand 87 $4,109
Lisdexamfetamine Dimesylate Generic 19 $3,089
Klonopin Clonazepam Brand 12 $3,051
Venlafaxine Hcl Er Venlafaxine Hcl Brand 67 $2,985
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 50 $2,806
Quetiapine Fumarate Generic 98 $2,617

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$65,621

Medicare's payments for the services billed

Medicare patients

147

Average age 68

Services billed

919

95 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 61%
Arthritis 52%
Diabetes 25%
Chronic kidney disease 20%
Ischemic heart disease 19%
Osteoporosis 16%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$552 28 —
REXULTI
$317 — —
CAPLYTA
$259 — —
FANAPT
$193 — —
SPRAVATO
$193 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

587 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record